CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05228015
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:08.120788+00:00
Published At: 2024-11-18T00:00:00+00:00
Record Updated At: 2024-11-18
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Solid Tumors, Adult", "Solid Tumor", "Malignant Pleural Mesothelioma (MPM)", "Epithelioid Hemangioendothelioma (EHE)", "NF2 Deficient Mesothelioma", "Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes", "NF2 Deficiency", "YAP1 or TAZ Gene Fusions"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-11-18"
protocolSection.identificationModule.nctId: "NCT05228015"
protocolSection.identificationModule.officialTitle: "A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.